Politics & Business | Page 7 of 9

Sanofi-aventis and UCSF to Collaborate on Development of Diabetes Therapies

The University of California, San Francisco (UCSF) and sanofi-aventis have formed two new research and development collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient. The first collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation...

Eli Lilly and Boehringer Ingelheim to Develop and Market New Diabetes Drugs

Eli Lilly and Company and Boehringer Ingelheim announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim's two oral diabetes agents—linagliptin and BI10773—as well as Lilly's two basal insulin analogues—LY2605541 and LY2963016—as well as the option to co-develop and co-commercialize Lilly's anti-TGF-beta monoclonal antibody....

Haiti’s Diabetics One Year After The Earthquake

During the earthquake, 90 percent of diabetes patients lost their medication. However, under the leadership of International Diabetes Federation (IDF) and diabetes associations worldwide...

Sanofi-aventis Acquires Next Generation Drug Delivery Technology for Diabetes Treatment

Sanofi-aventis announced it has signed a global licensing and patent transfer agreement with Ascendis Pharma (Ascendis) on Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology, which allows for a drug compound to be released in the body in a precise, time-controlled fashion, creating a long-acting effect...

Novo Nordisk to Sponsor Diabetes Leadership Forum in Dubai

The Middle East and Northern Africa (MENA) region is facing one of the greatest healthcare challenges of our time: the diabetes pandemic. It is estimated that 26.6 million people in the region have diabetes and this number is set to double to 51.7 million by 2030. To help find solutions to this challenge, Novo Nordisk is sponsoring a Diabetes Leadership Forum on 12-13 December in Dubai. At the Forum, a group of over 600 regional...

Native Americans’ Health Care Under Funded According to Novo Nordisk BlueSheet

The fourth issue of the Novo Nordisk BlueSheet examines the disparity in diabetes prevention and care in racial and ethnic communities in the US, highlighting the Native American Communities which have one of the highest rates of diabetes in the country. Featured is an interview with Dr. Donald Warne, director of the Office of Native American Health at Sanford Health...

Half of Americans Will Suffer from Diabetes or Prediabetes by 2020 at a Cost of $3.35 Trillion

A new report by UnitedHealth Group’s Center for Health Reform & Modernization estimates that more than 50 percent of Americans could have diabetes or prediabetes by 2020 at a cost of $3.35 trillion over the next decade if current trends continue. If this estimate is correct diabetes and prediabetes will account for an estimated 10 percent ...

Lilly to Open Diabetes Research Center in Shanghai, China

Eli Lilly has announced plans to open a diabetes research center in Shanghai, China. The center, planned to open in the second half of 2011, will focus on discovering new medicines to treat diabetes. According to a recent article in The New England Journal of Medicine, an estimated 92 million people in China - almost 10 percent of the adult population - have diabetes...

Dealing in Diabetes: Inside the Pharmaceutical Industry, From a Patient’s Perspective

I am evaluated on my ability to move numbers as a sales person, but I am a patient advocate first...

Novo Nordisk Spends $375k Lobbying US Government

Danish drugmaker Novo Nordisk, the world's top producer of insulin, spent $375,000 lobbying the U.S. government in the second quarter of 2010 on several diabetes-related issues, among other topics, according to a Bloomberg report

Category: Politics & Business